Department of Experimental Medicine, Second University of Naples, Via Costantinopoli 16, Naples, Italy.
Naunyn Schmiedebergs Arch Pharmacol. 2010 Sep;382(3):287-91. doi: 10.1007/s00210-010-0545-2. Epub 2010 Aug 8.
The purpose of this study is to investigate whether an oxygen/ozone (O(2)/O(3)) mixture protects the heart from acute myocardial infarction through local involvement of endothelial nitric oxide synthase (eNOS) and endothelial progenitor cells (EPCs). Male Sprague-Dawley rats were subject to 25-min occlusion and 2-h reperfusion of the left descending coronary artery. O(2)/O(3) mixture was insufflated i.p. 30 min prior to ischemia/reperfusion (I/R) procedure at doses of 100, 150, and 300 microg/kg. Myocardial infarct size (IS) measurement and myocardial immunohistochemistry for EPCs were done. For these latter cells, immunoreactivities for CD34, and CD117/c-kit were assessed within the infarcted tissue. Moreover, cardiac eNOS was monitored. I/R in rats treated with O(2) produced an IS as a percentage of the area at risk (IS/AR) equal to 51 +/- 5%. I/R in rats treated with the O(2)/O(3) mixture showed reduced IS (for example, IS/AR for 150 microg/kg O(2)/O(3) was 35 +/- 2.1%; P < 0.01 vs. O(2)). The O(2)/O(3) cardio-protection was paralleled by an increased number of immunopositive particles per area for CD34 and CD117/c-kit. The increase of these markers was associated with an increase of cardiac eNOS expression as assayed by immunohistochemistry. Interestingly, N5-(1-Iminoethyl)-L-ornithine dihydrochloride (L-NIO), a selective eNOS activity inhibitor (30 mg/kg s.c.), prior to O(2)/O(3) and I/R almost abolished the cardio-protection exerted by the O(2)/O(3) mixture. L-NIO also abolished the increase in immunostaining for CD-34 and CD117/c-kit as compared with the rats receiving O(2)/O(3) and I/R only. O(2)/O(3) mixture protects the heart from acute myocardial infarction through local increase of eNOS expression/activity and consequent EPCs recruitment.
本研究旨在探讨氧气/臭氧(O(2)/O(3))混合物是否通过局部内皮型一氧化氮合酶(eNOS)和内皮祖细胞(EPCs)的参与来保护心脏免受急性心肌梗死。雄性 Sprague-Dawley 大鼠接受左冠状动脉前降支 25 分钟闭塞和 2 小时再灌注。O(2)/O(3)混合物在缺血/再灌注(I/R)程序前 30 分钟通过腹腔内注射以 100、150 和 300μg/kg 的剂量给药。进行心肌梗塞面积(IS)测量和心肌组织 EPCs 的免疫组织化学染色。对于这些细胞,在梗塞组织内评估 CD34 和 CD117/c-kit 的免疫反应性。此外,监测心脏 eNOS。用 O(2)处理的大鼠的 I/R 产生的梗塞面积与危险区域(IS/AR)的百分比相等,为 51 +/- 5%。用 O(2)/O(3)混合物处理的大鼠的 I/R 显示梗塞面积减少(例如,150μg/kg O(2)/O(3)的 IS/AR 为 35 +/- 2.1%;P < 0.01 与 O(2)相比)。O(2)/O(3)的心脏保护作用与免疫组织化学检测到的心脏 eNOS 表达增加相平行。有趣的是,N5-(1-亚氨基乙基)-L-鸟氨酸二盐酸盐(L-NIO),一种选择性 eNOS 活性抑制剂(30mg/kg 皮下注射),在 O(2)/O(3)和 I/R 之前给药,几乎消除了 O(2)/O(3)混合物产生的心脏保护作用。与仅接受 O(2)/O(3)和 I/R 的大鼠相比,L-NIO 还消除了 CD-34 和 CD117/c-kit 免疫染色的增加。O(2)/O(3)混合物通过局部增加 eNOS 表达/活性和随后的 EPC 募集来保护心脏免受急性心肌梗死。